Incubating in China

Why C-Bridge is writing big checks to bring Western platforms into China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing larger sums of capital into a relatively small portfolio.

And while C-Bridge cut its teeth on more established companies, the firm is now setting its sights on building more companies from the ground up. Its two most recent investments -- Everest Medicines Ltd. and CMAB Biopharma Inc. -- are examples.

CEO and Managing Director Fu Wei founded C-Bridge in 2014. Fu was previously head of principal investment at Far East Horizon.

C-Bridge’s first fund raised $185 million, and last May the firm closed its second fund at $400 million, well above

Read the full 1254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers